Compare DigitalOcean Holdings Inc (DOCN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DigitalOcean Holdings Inc vs Recursion Pharmaceuticals Inc — how do they compare? DigitalOcean Holdings Inc trades at $123.24 (market cap $13.18B), while Recursion Pharmaceuticals Inc trades at $3.38 (market cap $1.78B). The key difference: DigitalOcean Holdings Inc is far larger — about 7.4× Recursion Pharmaceuticals Inc's market cap, and DigitalOcean Holdings Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| DOCN | RXRX | |
|---|---|---|
Market Cap | $13.18B | $1.78B |
Sector | Technology | Health |
52-Week High | $181.29 | $6.79 |
52-Week Low | $25.74 | $2.84 |
Enterprise Value | $13.74B | $1.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DigitalOcean (DOCN) trades at $123.32, down 5.49% today, with bearish technical signals but strong fundamental performance. The company reported record Q2 2026 results with revenue exceeding expectations and significant AI-driven growth. Analyst consensus remains bullish with a $174.80 price target, though technical indicators show selling pressure near-term.
The outlook remains positive given strong AI adoption and enterprise wins, with 63% analyst buy ratings supporting upside potential. Key risks include high valuation multiples and competitive cloud market pressures. The stock's current weakness presents a potential entry point for growth investors seeking AI infrastructure exposure.
RXRX trades at $3.30, down 7.3% today, with bearish technical signals from moving averages and oscillators. The clinical-stage biotech shows severe financial strain with a -851.51% net income margin and negative cash flow from operations of -$372M in 2025, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights AI-driven drug discovery potential but questions commercial viability.
Despite analyst consensus price target of $7.83 suggesting 137% upside, high cash burn and unproven business model pose substantial risk. Investment appeal hinges on successful drug development milestones, but current fundamentals indicate speculative positioning suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DigitalOcean Holdings Inc
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Read more on DOCN →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
